Clinical Trial Update: A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and pharmacology of the PI3-kinase inhibitor pictilisib (GDC-0941) in combination with chemotherapy regimens with or without bev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• PACLITAXEL (PACLITAXEL)
• Pemetrexed (pemetrexed)
• pictilisib (GDC-0941) (pictilisib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED